{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:04:02Z","timestamp":1791255842045,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.bulcan.2015.12.003","type":"journal-article","created":{"date-parts":[[2016,1,25]],"date-time":"2016-01-25T16:45:34Z","timestamp":1453740334000},"page":"127-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rationnel et modalit\u00e9s de prescription de l\u2019ibrutinib dans les h\u00e9mopathies lympho\u00efdes B"],"prefix":"10.1016","volume":"103","author":[{"given":"Aurore","family":"Doug\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Ravinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Olivier","family":"Bay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Gui\u00e8ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Lemal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.bulcan.2015.12.003_bib0255","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1182\/blood-2014-07-586826","article-title":"Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?","volume":"124","author":"Dreger","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2015.12.003_bib0260","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ajh.23491","article-title":"Chronic lymphocytic leukemia: 2013\u00a0update on diagnosis, risk stratification and treatment","volume":"88","author":"Hallek","year":"2013","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.bulcan.2015.12.003_bib0265","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1038\/leu.2014.171","article-title":"How to manage mantle cell lymphoma","volume":"28","author":"Dreyling","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bulcan.2015.12.003_bib0270","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1586\/17474086.2014.951323","article-title":"Ibrutinib for the treatment of mantle cell lymphoma","volume":"7","author":"Shah","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1016\/j.bulcan.2015.12.003_bib0275","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2015-01-553974","article-title":"How I treat Waldenstr\u00f6m macroglobulinemia","volume":"126","author":"Treon","year":"2015","journal-title":"Blood"},{"issue":"6409","key":"10.1016\/j.bulcan.2015.12.003_bib0280","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/361226a0","article-title":"The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases","volume":"361","author":"Vetrie","year":"1993","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bulcan.2015.12.003_bib0285","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2015.12.003_bib0290","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2162-3619-3-4","article-title":"Ibrutinib for B cell malignancies","volume":"3","author":"Novero","year":"2014","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2015.12.003_bib0295","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"10.1016\/j.bulcan.2015.12.003_bib0300","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1182\/blood.V124.21.3310.3310","article-title":"Ibrutinib inhibits concomitant TLR and BCR-driven proliferation of chronic lymphocytic leukemia cells and overrides the supportive survival-promoting effects of microenvironmental signals","volume":"124","author":"Temburni","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2015.12.003_bib0305","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2006.11.012","article-title":"Bruton's tyrosine kinase and phospholipase Cgamma2\u00a0mediate chemokine-controlled B cell migration and homing","volume":"26","author":"De Gorter","year":"2007","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.bulcan.2015.12.003_bib0310","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1517\/14656566.2013.780031","article-title":"Protein kinase inhibitors against malignant lymphoma","volume":"14","author":"D\u2019Cruz","year":"2013","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.bulcan.2015.12.003_bib0315","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765\u00a0thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.bulcan.2015.12.003_bib0320","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765\u00a0blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"10.1016\/j.bulcan.2015.12.003_bib0325","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1182\/blood.V124.21.326.326","volume":"124","author":"Burger","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2015.12.003_bib0330","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2015.12.003_bib0335","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","article-title":"Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2\u00a0trial","volume":"15","author":"O\u2019Brien","year":"2014","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.bulcan.2015.12.003_bib0340","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Chang","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2015.12.003_bib0345","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.bulcan.2015.12.003_bib0350","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2015.12.003_bib0355","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood.V124.21.327.327","article-title":"Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE\u2122-17\u00a0trial","volume":"124","author":"O\u2019Brien","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2015.12.003_bib0360","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53\u00a0aberrations: a phase 2, single-arm trial","volume":"16","author":"Farooqui","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2015.12.003_bib0365","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2015.12.003_bib0370","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.bulcan.2015.12.003_bib0375","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m's macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.bulcan.2015.12.003_bib0380","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2015.12.003_bib0385","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"24","key":"10.1016\/j.bulcan.2015.12.003_bib0390","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.bulcan.2015.12.003_bib0395","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.bulcan.2015.12.003_bib0400","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1182\/blood-2014-08-592725","article-title":"Ibrutinib-na\u00efve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance","volume":"124","author":"Fam\u00e0","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2015.12.003_bib0405","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood-2015-03-585075","article-title":"Targeted therapies in CLL: mechanisms of resistance and strategies for management","volume":"126","author":"Woyach","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2015.12.003_bib0410","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2015.12.003_bib0415","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.bulcan.2015.12.003_bib0420","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.bulcan.2015.12.003_bib0425","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V124.21.22.22","article-title":"Complex karyotype, rather than del(17p), is associated with inferior outcomes in relapsed or refractory CLL patients treated with ibrutinib-based regimens","volume":"124","author":"Thompson","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bulcan.2015.12.003_bib0430","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","article-title":"MYD88\u00a0mutations and response to ibrutinib in Waldenstr\u00f6m's macroglobulinemia","volume":"373","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2015.12.003_bib0435","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.13200","article-title":"CXCR4\u00a0WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P)-directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells","volume":"168","author":"Cao","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.bulcan.2015.12.003_bib0440","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjh.13427","article-title":"Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"170","author":"Zhang","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bulcan.2015.12.003_bib0445","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3324\/haematol.2014.107011","article-title":"Ibrutinib interferes with the cell-mediated anti-tumour activities of therapeutic CD20\u00a0antibodies: implications for combination therapy","volume":"100","author":"Da Roit","year":"2015","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.bulcan.2015.12.003_bib0450","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood.V124.21.3117.3117","article-title":"Effects of ibrutinib on rituximab and GA-101\u00a0induced antibody-dependent cell cytotoxicity (ADCC) in lymphoma cells in vitro","volume":"124","author":"Davis","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2015.12.003_bib0455","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1182\/blood.V124.21.1186.1186","article-title":"Ibrutinib treatment of relapsed CLL following allogeneic transplantation: sustained disease response and promising donor immune modulation","volume":"124","author":"Ryan","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2015.12.003_bib0460","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1182\/blood.V124.21.4697.4697","article-title":"Safety and efficacy of ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma who have undergone prior allogeneic stem cell transplant","volume":"124","author":"Coutre","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2015.12.003_bib0465","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2015.12.003_bib0470","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/blood.V124.21.1987.1987","article-title":"A dose escalation study of ibrutinib with lenalidomide for relapsed and refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"124","author":"Pollyea","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bulcan.2015.12.003_bib0475","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.bulcan.2015.12.003_bib0480","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2014-09-585869","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia","volume":"125","author":"Brown","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2015.12.003_bib0485","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1182\/blood-2014-12-617522","article-title":"Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b\/2\u00a0study","volume":"126","author":"Jaglowski","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2015.12.003_bib0490","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V124.21.627.627","article-title":"Ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a phase II clinical trial","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bulcan.2015.12.003_bib0495","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2\u00a0study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.bulcan.2015.12.003_bib0250","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1182\/blood.V124.21.4679.4679","article-title":"Ublituximab (TG-1101), a novel glycoengineered anti-CD20\u00a0monoclonal antibody, in combination with ibrutinib is highly active in patients with relapsed and\/or refractory CLL and MCL; results of a phase II trial","volume":"124","author":"Sharman","year":"2014","journal-title":"Blood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115003756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455115003756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T06:46:04Z","timestamp":1600065964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455115003756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0007455115003756"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2015.12.003","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationnel et modalit\u00e9s de prescription de l\u2019ibrutinib dans les h\u00e9mopathies lympho\u00efdes B","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2015.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}